MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 12-06-2025
Insulet Corporation Cost of Revenue 2011-2025 | PODD
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Insulet Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 347 M | 322 M | 258 M | 194 M | 187 M | 156 M | 131 M | 104 M | 95.4 M | 119 M | 85.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 347 M | 85.5 M | 182 M |
Quarterly Cost of Revenue Insulet Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 196 M | 197 M | - | - | 167 M | 158 M | - | - | - | - | - | - | - | - | 85.7 M | - | 86.9 M | 80.5 M | 84.8 M | - | 82.2 M | 83.8 M | 71.1 M | - | 69 M | 60.7 M | 52.9 M | - | 49.1 M | 42.2 M | 47.8 M | - | 48.2 M | 45.1 M | 42.3 M | - | 39.2 M | 36.9 M | 37.2 M | - | 39.8 M | 30 M | 19 M | - | 36.9 M | 36.2 M | 36.4 M | - | 33.7 M | 33.3 M | 32.2 M | - | 30.4 M | 28.7 M | 27.5 M | - | 26 M | 17.7 M | 14.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 197 M | 14.7 M | 60.7 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
162 M | - | - | $ 17.2 B |  USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Apyx Medical Corporation
APYX
|
18.6 M | $ 3.86 | -3.26 % | $ 134 M | USA |
 |
Bio-Rad Laboratories
BIO
|
1.19 B | $ 307.92 | -1.93 % | $ 8.69 B | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 45.13 | -2.67 % | $ 6.72 K | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Abbott Laboratories
ABT
|
18.7 B | $ 125.1 | 1.48 % | $ 218 B | USA |
 |
Boston Scientific Corporation
BSX
|
5.26 B | $ 92.34 | 0.64 % | $ 136 B | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 2.56 | 8.94 % | $ 95.5 M |  France |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
56.1 M | $ 17.7 | -3.46 % | $ 408 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Xtant Medical Holdings
XTNT
|
49.1 M | $ 0.73 | 4.33 % | $ 97.6 M | USA |
 |
InMode Ltd.
INMD
|
77.8 M | $ 14.56 | 0.76 % | $ 1.15 B |  Israel |
 |
Cognyte Software Ltd.
CGNT
|
104 M | $ 9.88 | 0.05 % | $ 709 M | Israel |
 |
Second Sight Medical Products
EYES
|
11.8 M | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
1.2 B | $ 165.15 | 0.78 % | $ 12.4 B | USA |
 |
Accuray Incorporated
ARAY
|
312 M | $ 1.07 | -3.18 % | $ 110 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
12.3 M | $ 12.81 | -1.23 % | $ 346 M | USA |
 |
AxoGen
AXGN
|
45.4 M | $ 30.33 | 1.15 % | $ 1.34 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
CONMED Corporation
CNMD
|
574 M | $ 40.78 | 2.33 % | $ 1.26 B | USA |
 |
Globus Medical
GMED
|
1.04 B | $ 86.83 | -2.31 % | $ 11.8 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
728 M | $ 13.41 | -4.56 % | $ 1.03 B | USA |
 |
Aziyo Biologics
AZYO
|
13.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Alphatec Holdings
ATEC
|
187 M | $ 20.04 | 0.65 % | $ 2.86 B | USA |
 |
Aethlon Medical
AEMD
|
3.87 M | $ 3.4 | - | $ 5.31 M | USA |
 |
Establishment Labs Holdings
ESTA
|
56.5 M | $ 72.58 | -0.19 % | $ 2.04 B |  Costa-rica |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 0.92 | -4.72 % | $ 14.8 M | USA |
 |
Electromed
ELMD
|
14 M | $ 29.74 | 0.64 % | $ 251 M | USA |
 |
IRadimed Corporation
IRMD
|
16.9 M | $ 96.35 | -1.06 % | $ 1.22 B | USA |